taulogo

Company News

 

Tauriga Sciences Inc. to Form Wholly Owned Subsidiary Focused on the Development …  View


Tauriga Sciences, Inc. announced that it has secured additional capital..  View


2014 – 2015 Financials Reported – Company On Track To Regain Reporting Status. View

LATEST TAURIGA SCIENCES UPDATES

TAURIGA SCIENCES, INC. REPORTS PROGRESS IN COMPLETING THE FORMULATION OF ITS FIRST COLLUMAUXIL BRANDED PRODUCT, A CANNABIDIOL “CBD” INFUSED ROLL ON FOR MUSCLE TENSION RELIEF

LOS ANGELES, CA–(Marketwired – Dec 7, 2016) – Tauriga Sciences, Inc. (OTC PINK: TAUG) (“Tauriga” or the “Company”), a company engaged in building businesses in the life sciences space,…

Read More

NEW YORK, NY–(Marketwired – Nov 15, 2016) – Tauriga Sciences, Inc. (OTC PINK: TAUG) (“Tauriga” or the “Company”), a life sciences technology Company, announced that it will form a new wholly owned subsidiary focused on the development, marketing and distribution of products that target muscle tension.

Read More

CORRECTION – TAURIGA SCIENCES INC.

NEW YORK, NY–(Marketwired – Nov 9, 2016) – In the news release, issued earlier today by Tauriga Sciences, Inc. ( OTC PINK : TAUG ), we are advised by the company the headline should read “Tauriga Sciences Inc. Files its Form 10-Q for 1st Fiscal Quarter of 2017” rather than “Tauriga Sciences Inc. Files its Form 10-Q for 1st Fiscal Quarter of 2016” as originally issued. Complete corrected text follows.

Tauriga Sciences Inc. Files its Form 10-Q for 1st Fiscal Quarter of 2017

NEW YORK, NY — November 9, 2016 — Tauriga Sciences, Inc. (OTC PINK: TAUG)

Read More

Fully committed to commercializing innovation to enhance personal wellness, improve our environment and create lasting shareholder value.

Balanced Innovation and Commercialization

Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues in the natural wellness sector and on developing a proprietary synthetic biology platform technology through its wholly-owned Pilus Energy subsidiary.

The Company’s business model is to create an attractive and balanced portfolio of life sciences assets without typical clinical regulatory timelines.

box2
Tauriga’s main focus for the last year has been getting audited financials and relisted on BB. Due to what we believe was gross malpractice by our auditors, TAUG was delisted from the BB. But we are always looking for exciting opportunities to increase shareholder value.
box2a
Tauriga Sciences, Inc. (OTC PINK: TAUG) (“Tauriga” or the “Company”), a diversified life sciences technology Company, today announced that it has completed an equity private placement for $105,500 USD to date comprised of accredited individual investors as well as one institutional investor.
box3
Recently the Company added Frank Orlowski, Sr. Director at Pfizer (PFE); and Keith Berman  CEO of Digital Diagnostics Inc (DECN). The Company remains committed to finding the right opportunity to joint venture or merge with.